@article{c586e27f07c24174b4f0511826e060ad,
title = "MOG-IgG among participants in the pediatric optic neuritis prospective outcomes study",
author = "\{Pediatric Eye Disease Investigator Group (PEDIG)\} and Chen, \{John J.\} and Pineles, \{Stacy L.\} and Repka, \{Michael X.\} and Pittock, \{Sean J.\} and Henderson, \{Robert J.\} and Liu, \{Grant T.\}",
note = "Funding Information: Conflict of Interest Disclosures: Dr Pittock reports grants from Grifols and the Autoimmune Encephalitis Alliance; honoraria and travel expenses from MedImmune, Inc and Alexion Pharmaceuticals, Inc; consulting fees from Astellas; personal fees from Genentech Sage Therapeutics, and Prime Therapeutics, UCB, Inc, and Hoffman/LaRoche AG; and consulting compensation from Euroimmun outside the submitted work; and has patents 8,889,102 for neuromyelitis optica autoantibodies as a marker for neoplasia and 9,891,219B2 for methods for treating neuromyelitis optica by administration of eculizumab to an individual that is aquaporin-4-IgG autoantibody positive; and pending patents for GFAP-IgG, Septin-5-IgG, MAP1B-IgG, Kelch-like protein 11, and PDE10A. No other disclosures were reported. Funding/Support: This research was supported by grants EY011751, EY018810, and EY023198 from the National Eye Institute. Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.",
year = "2021",
month = may,
doi = "10.1001/jamaophthalmol.2021.0349",
language = "English (US)",
volume = "139",
pages = "583--585",
journal = "JAMA Ophthalmology",
issn = "2168-6165",
publisher = "American Medical Association",
number = "5",
}